Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
QuintilesIMS
Colorcon
Covington
US Army
US Department of Justice

Generated: September 16, 2019

DrugPatentWatch Database Preview

Patent: 9,700,595

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,700,595
Title:Liquid formulation of a fusion protein comprising TNFR and Fc region
Abstract: The present invention relates to a liquid formulation comprising a TNFR-Fc fusion protein and a stabilizer, in which the fusion protein comprises TNFR (tumor necrosis factor receptor) or a fragment thereof and an immunoglobulin Fc region, and the stabilizer comprises one or more amino acids selected from the group consisting of proline and histidine, a buffer solution, and an isotonic agent containing sodium chloride (NaCl) and sucrose, and a preparation method of the liquid formulation. The liquid formulation according to the present invention provides excellent storage stability because long-term storage of TNFR-Fc fusion protein (etanercept) is possible and particular storage conditions are not needed. Since the liquid formulation of the present invention shows excellent storage stability even though the formulation is simple, it is more economical than other stabilizers or lyophilized formulations, and thus the formulation can be effectively applied for uses wherein treatment of TNFR-Fc fusion protein (etanercept) is beneficial.
Inventor(s): Lee; Jung Tae (Yuseong-gu, KR), Kim; In Hyuk (Daejeon, KR), Yu; Jae Keun (Incheon, KR), Yim; Jung Yim (Daejeon, KR), Jeong; Myeong Hyeon (Daejeon, KR), Ahn; Yong Ho (Daejeon, KR)
Assignee: ARES TRADING SA (Aubonne, CH)
Application Number:15/038,953
Patent Claims:see list of patent claims

Details for Patent 9,700,595

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Try a Free Trial ARES TRADING SA (Aubonne, CH) 2033-11-29 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   Try a Free Trial ARES TRADING SA (Aubonne, CH) 2033-11-29 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Accenture
QuintilesIMS
Fuji
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.